News

Onyx Pharmaceuticals has rejected an unsolicited takeover bid from Amgen, worth in the region of $8.70 billion, but is talking with other potential suitors.

The US Food and Drug Administration has granted breakthrough therapy designation to GlaxoSmithKline’s drisapersen for the potential treatment of patients with Duchenne muscular dystrophy.

Roche has signed up to get access to the T cell receptor technology created by Immunocore, an oncology deal which could prove to be highly lucrative for the UK firm.

The US Supreme Court has ruled that generic drugmakers cannot be sued by patients who suffer adverse reactions caused by their products, because the companies did not develop the drugs nor seek their initial approval.

South Africa’s generic drug giant Aspen has hit the acquisition trail again, this time snapping up a selection of drugs and a manufacturing plant from MSD for around $1 billion.

The US Food and Drug Administration has given the green light to Baxter International’s Rixubis, the first new recombinant factor IX approved for haemophilia B in more than 15 years.

US-based patient-recruitment specialist BBK Worldwide has launched a new online tool that leverages Google’s virtual tours facility to improve engagement with potential study participants.

Celgene Corp has signed a multiple myeloma and leukaemia pact with MorphoSys that could be worth up to 628 million euros to the German biotech.

Findings of a national audit have painted a “shocking” picture of the state of care patients with diabetes receive in hospital, which is putting their safety at risk.

Ireland’s new legislation to establish systems of reference pricing and generic substitution takes effect this week, and the first reference prices, for atorvastatin product, will be implemented in November, Ministers have said.

PRA International is sticking with private ownership after announcing that funds managed by investment firm KKR will acquire the US-based clinical research organisation from Genstar Capital.

UK regulators have seized a record haul of counterfeit and unlicensed medicines – worth a massive £12.2 million.

A leading business expert has attacked doctors for their opposition to suggestions that the NHS should operate as a seven-day-a-week, supermarket-style service.

The number of new commercial-contract studies supported by the National Institute for Health Research Clinical Research Network (NIHR CRN) in England rose by 17% year on year to 455 in 2012/13, the Network’s latest annual statistics show.

Some three years after regulators in the USA rejected flibanserin, Sprout Pharmaceuticals has resubmitted the female sexual dysfunction drug acquired from Boehringer Ingelheim to the Food and Drug Administration.